Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

@article{Henry2009EffectOT,
  title={Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.},
  author={Robert R. Henry and Abraham Michael Lincoff and Sunder Raj D Mudaliar and Michael Rabbia and Cathy Chognot and M. M. Herz},
  journal={Lancet},
  year={2009},
  volume={374 9684},
  pages={126-35}
}
BACKGROUND Despite previous reports of potential adverse cardiovascular effects of peroxisome proliferator-activated receptor (PPAR) agonists, the promise for PPAR agonists to positively affect risk of cardiovascular disease in patients with type 2 diabetes is of continued interest. The SYNCHRONY study aimed to establish the glucose-lowering and lipid-modifying effects, and safety profile, of the dual PPAR-alpha and PPAR-gamma agonist aleglitazar. METHODS In this double-blind study, patients… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
63 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

Similar Papers

Loading similar papers…